In The Media…

Targeted Oncology

December 03, 2021

Prostate cancer biopsies performed with the PrecisionPoint™ Transperineal Access System result in about 30% better cancer detection rates and a nearly 0% infection rate by safely and accurately sampling the entire prostate. As part of #NoShaveNovember, founder and CEO of Perineologic, Dr. Matthew Allaway discussed why expanded adoption of the transperineal approach is critical to support early detection of prostate cancer in this Targeted Oncology article.

Have a Question? Contact Us!

Thank you for your interest in Perineologic®!

Other Ways to Contact Us

ML-001-03revB